Commercial code

Voting Rights and Shares Capital of the Company

Retrieved on: 
Tuesday, February 13, 2024
Commercial code, Nanobiotix

PARIS, Feb. 13, 2024 (GLOBE NEWSWIRE) --

Key Points: 

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors

Retrieved on: 
Friday, February 9, 2024
Health, Medical Devices, Genetics, Research, Science, Pharmaceutical, Biotechnology, Stifel, Sofinnova, Ototoxicity, Quality of life, GJB2, Huber loss, Euronext Growth, Code, Chair, SVB Securities, EUR, Pasteur Institute, Clinical trial, Patient, Reserved, Person, Commercial code, Audiology

The settlement-delivery of the Reserved Offering is expected to take place around February 13, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around February 13, 2024, subject to customary conditions.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “We are delighted to announce today’s successful capital raise of EUR 50.5 million.
  • This strengthened shareholder base reinforces Sensorion’s ambition to advance its pipeline of innovative therapies intended to improve the quality of life of patients suffering from hearing disorders.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

RALLYE S.A.: Arrangements for making documents available at the Shareholders’ Meeting of 12 February 2024

Retrieved on: 
Tuesday, January 30, 2024
Bulletin, Rallying, Commercial code, Marriott Hotels & Resorts, Shareholder, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The Notice of Meeting was published in the Bulletin des Annonces Légales Obligatoires of 22 January 2024 (Bulletin n°10) and in the Actu-Juridique support of the same day.
  • The procedures for participation and voting at this Meeting are set out in this notice.
  • Information and documents relating to this Meeting can be found on the Company’s website: https://www.rallye.fr /
    All documents and information concerning this Meeting are made available to the Shareholders under the conditions provided for by the regulations in force.

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Retrieved on: 
Tuesday, January 16, 2024
Euronext, Finance, UCART123, Form, Tranche, Commercial code, EIB, Form 6-K, Exercise, BofA Securities, European Investment Bank, Security (finance)

Tranche B is expected to be disbursed by the EIB by January 25, 2024.

Key Points: 
  • Tranche B is expected to be disbursed by the EIB by January 25, 2024.
  • The Company plans to use the proceeds of Tranche B towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, and UCART123.
  • The total number of shares issuable upon exercise of the Tranche B Warrants represents circa 2% of the Company’s outstanding share capital as at their issuance date.
  • Tranche B will mature six years from its disbursement date and will accrue interest at a rate of 7% per annum capitalized annually and payable at maturity.

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

Retrieved on: 
Wednesday, January 10, 2024
Patient, Partnership, Finance, Fatty liver disease, Sale, Drug development, Commercial code, EIB, NASH, Exercise, BofA Securities, European Investment Bank, Pharmaceutical industry

The disbursement of the second tranche is expected to occur on or about January 18, 2024.

Key Points: 
  • The disbursement of the second tranche is expected to occur on or about January 18, 2024.
  • On January 4, 2024, and in accordance with the Finance Contract, the Company issued 3,144,654 warrants to EIB.
  • After the drawdown of the first tranche in December 20222, the Company was eligible to access the second tranche of €25 million if it met certain conditions precedent described below.
  • Following the achievement of those conditions, the Company decided to draw on the second tranche to reinforce its financial position.

TaTaTu S.p.A.: TERMINATION OF THE LIQUIDITY CONTRACT DATED 09/22/2022 WITH EXANE AND IMPLEMENTATION OF A NEW CONTRACT OF LIQUIDITY WITH KEPLER CHEUVREUX

Retrieved on: 
Wednesday, January 3, 2024
TaTaTu, Council, Euronext Paris, Agreement, MAR, Liquidity, European, Public offering, European Parliament, Calendar, Commercial code, AMF

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Tatau S.p.A, and Kepler Cheuvreux (the “New Liquidity Provider”) have signed on December 21, 2023 a liquidity contract regarding the liquidity of Tatatu S.p.A shares admitted to Euronext Paris (the “Agreement”).
  • The implementation of the Agreement will be carried out in accordance with the legal provisions in force, and more specifically with the provisions of Regulation (EU) No.
  • This press release and the corporate events calendar are available on the Company's website at the following address https://corporate.tatatu.com/en/corporate/ Investors section/Financial Calendar.

Voting Rights and Shares Capital of the Company

Retrieved on: 
Wednesday, December 13, 2023
Nanobiotix, Commercial code

PARIS, Dec. 13, 2023 (GLOBE NEWSWIRE) --

Key Points: 

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

Retrieved on: 
Monday, December 4, 2023
Initial, ADS, Partnership, Janssen, Cancer, Code, Commercial code, Patient, Common stock, NANO, American depositary receipt, Security (finance)

The subscription by JJDC of the Remaining Placement Amount was conditioned upon the approval of the French Ministry of Economy.

Key Points: 
  • The subscription by JJDC of the Remaining Placement Amount was conditioned upon the approval of the French Ministry of Economy.
  • The Company intends to use the net proceeds from the Remaining Placement as described in the Company’s press release dated November 6, 2023.
  • On an illustrative basis, a shareholder which held 1% of the Company’s share capital before the Remaining Placement holds a stake of0,98% after closing of the Remaining Placement.
  • The following table presents, to the Company’s knowledge, the expected allocation of the Company’s share capital following the closing of the Remaining Placement:

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

Retrieved on: 
Monday, December 4, 2023
Initial, ADS, Partnership, Janssen, Cancer, Code, Commercial code, Patient, Common stock, NANO, American depositary receipt, Security (finance)

The subscription by JJDC of the Remaining Placement Amount was conditioned upon the approval of the French Ministry of Economy.

Key Points: 
  • The subscription by JJDC of the Remaining Placement Amount was conditioned upon the approval of the French Ministry of Economy.
  • The Company intends to use the net proceeds from the Remaining Placement as described in the Company’s press release dated November 6, 2023.
  • On an illustrative basis, a shareholder which held 1% of the Company’s share capital before the Remaining Placement holds a stake of0,98% after closing of the Remaining Placement.
  • The following table presents, to the Company’s knowledge, the expected allocation of the Company’s share capital following the closing of the Remaining Placement:

Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023

Retrieved on: 
Thursday, November 30, 2023
Health, Health Technology, Other Health, Managed Care, General Health, Clinical Trials, Biotechnology, Annual, Combined, Exercise, Bulletin, Commercial code, Annual general meeting, Email, Balo language, Mass meeting, Audit

In accordance with articles R.225-83 of the French Commercial Code, documents are available for the shareholders from the time the meeting is convened.

Key Points: 
  • In accordance with articles R.225-83 of the French Commercial Code, documents are available for the shareholders from the time the meeting is convened.
  • For any questions relating to the Annual General Meeting of December 20, 2023, shareholders are invited to send an email to [email protected] .
  • The conditions for holding and taking part in this Combined Shareholders’ General Meeting may evolve depending on the health, regulatory and legal requirements in place.
  • In general, shareholders are invited to regularly consult the section dedicated to the General Meeting on the Company's website www.sensorion.com .